Grupo de trabajo en GESTIÓN DEL CONOCIMIENTO

Transcripción

1 Grupo de trabajo en GESTIÓN DEL CONOCIMIENTO Ferran Sanz Barcelona, 25 de mayo de 2006

2 The cost of drug discovery Reproduced from a presentation of Ian Ragan. EFPIA

3 The cost of drug discovery... and more than 10 years! Reproduced from a presentation of Ian Ragan. EFPIA

4 NCE approvals vs. R&D expenditures Reproduced from Service RF. Science 2004; 303: 1796.

5 R&D expenditure per geographic area Source: EFPIA, PhRMA, JPMA

6 Reproduced from a presentation of Octavi Quintana. EC

7 Reproduced from a presentation of Octavi Quintana. EC

8 Reproduced from a presentation of Octavi Quintana. EC

9 Reproduced from a presentation of Octavi Quintana. EC

10 Innovative Medicines Initiative Reproduced from a presentation of Ian Ragan. EFPIA

11 Innovative Medicines Initiative (Integrative) (Trans-disciplinary) Reproduced from a presentation of Ian Ragan. EFPIA

12 Knowledge management and integration Reproduced from a presentation of Ian Ragan. EFPIA

13 Knowledge management and integration Genomics Proteomics Combinatorial chemistry HTS (chemogenomics approaches) Reproduced from a presentation of Ian Ragan. EFPIA

14 Drug Discovery & Development has a great room for improvement on the basis of: the use of the omic knowledge and technologies the understanding of the therapeutic (as well as the sideeffects) mechanisms from the structural and systemic perspectives The use of information technologies for knowledge management and exploitation Ferran Sanz. 2006

15 IT tools along the Drug Life Cycle Target identification Target validation Identification & obtention of compounds Preclinical assessment Clinical trials Postmarketing monitoring Computational genomics Virtual screening Structurebased drug design ADMET prediction IM in clinical trials Computational systems biology FEATURES Biosimulation BENEFITS Stardardisation and interoperability Knowledge management and integration Ferran Sanz. 2006

16 Knowledge management and integration Integration of biomedical information in order to gain a more complete view of a disease, its pharmacological treatment or drug adverse event Disease Pathway Target Ligand Clinical information omics information Chemical information Ferran Sanz. 2006

17 Scientific requirements in KM Data federation: seamless search and navigation across heterogeneous data sources (private and public) Data integration: capacity to pool data from heterogeneous sources in a scientifically, semantically and mathematically consistent manner for further computation Sharing of services: integration and sharing of scientific tools (e.g., modelling, simulation) Reproduced from a presentation of Nicolas Grandjean. IMI

18 Overall architecture requirements Generic enough: to fit existing technical solutions and data sources, to accommodate existing and emerging data representation standards, to satisfynew and emerging requirements. Modular: to support integration of new resources in a standardised way (e.g., new data sources, new models, new ontologies, new scientific algorithms, new visualisation tools). Reproduced from a presentation of Nicolas Grandjean. IMI

19 Data sources Three categories: 1.Experimental proprietary data owned by companies, universities, hospitals, etc. 2.Highly curated, experimental-quality public domain data. 3.Publicly available, qualitative, documentarydata. Data in categories 1 and 2 can be pooled for data analysis, data mining, simulation, modelling, etc. Data belonging to category 3 can be used for qualitative data analysis and exploration, etc., but not for scientific computations. Reproduced from a presentation of Nicolas Grandjean. IMI

20 Global architecture Reproduced from a presentation of Nicolas Grandjean. IMI

21 Key topics of the European SAR in KM Translational Knowledge Management Data sharing Ontologies Interoperability of services Text mining Modeling and simulations Scientific knowledge representation (e.g., systems biology, disease models, etc.) Support to predictive efficacy and safety Clinical trial information management

22 Posibles campos de acción en España Inventariar y difundir la oferta tecnológica más avanzada y sus posibles proveedores en España (Coordinador: Carlos Martínez-Riera) Detectar necesidades reales de la industria farmacéutica española (Coordinador: un representante de la industria) Organizar workshops sobre temas específicos de GC (Coordinación y patrocinio: Genoma España / INB): Soporte bioinformático al descubrimiento y validación de dianas. La bioinformática y la informática biomédica en la investigación traslacional (descubrimiento y validación de biomarcadores, entre otros aspectos). El soporte bio/quimioinformatico al diseño de nuevos medicamentos, considerando tanto parámetros de eficacia como de seguridad. El soporte informático y computacional en el diseño y ejecución de ensayos clínicos. Promover proyectos de I+D que implique una amplia colaboración de diversos actores, por ejemplo: Compartir datos de toxicología resultantes de investigación pre-clínica (implica un cierto grado de anonimización irreversible de la información química). Compartir datos de ensayos clínicos.

23 Sesión sobre GC en I+D de medicamentos 4/7/06; 15:30-16:30 Moderadores: Josep Prous y repr. industria farmacéutica. Ponentes: Visión general y enfoque de la plataforma europea (Ferran Sanz) Oferta tecnológica existente en España (Carlos Martínez-Riera) La visión la Red Española de Informática Biomédica (Fernando Martín) La visión del Instituto Nacional de Bioinformática y propuesta de workshops (Alfonso Valencia).